(Q33291075)

25 July 2017

1 reference

retracted paper

0 references

title

WITHDRAWN: Antivirals for the common cold (English)

1 reference

25 July 2017

1 reference

T O Jefferson

1

1 reference

PubMed ID

17636705

25 July 2017

D Tyrrell

series ordinal

2

1 reference

25 July 2017

1 January 2001

1 reference

Cochrane Database of Systematic Reviews

25 July 2017

1 reference

25 July 2017

3

1 reference

25 July 2017

CD002743

1 reference

Effect of a Polynucleotide Interferon Inducer of Fungal Origin on Experimental Rhinovirus Infection in Humans

25 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Lack of Effect of an Interferon Inducer, N,N -Dihexadecyl- m -Xylylenediamine, on Rhinovirus Challenge in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Combined antiviral and antimediator treatment of rhinovirus colds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Intranasal pirodavir (R77,975) treatment of rhinovirus colds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

The preventive effect of human interferon-alpha preparation on upper respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Controlled trial of enviroxime against natural rhinovirus infections in a community

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Intranasal Lymphoblastoid Interferon ("Well fer on") Prophylaxis Against Rhinovirus and Influenza Virus in Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Trial of the antiviral action of isoprinosine against rhinovirus infection of volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Otologic effects of interferon beta serine in experimental rhinovirus colds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Antiviral effect of 3, 4-dihydro-1-isoquinolineacetamide hydrochloride in experimental human rhinovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Topical enviroxime against rhinovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Therapeutic activity of enviroxime against rhinovirus infection in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Effect of a Topical Interferon Inducer on Rhinovirus Infections in Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Effect of CP20,961, an Interferon Inducer, on Upper Respiratory Tract Infections Due to Rhinovirus Type 21 in Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002743.PUB2

Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Intranasal interferon for contact prophylaxis against common cold in families

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Therapeutic efficacy of inosiplex (Isoprinosine) in rhinovirus infection

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837)

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2 infection in human volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Human nasal mucosal responses to topically applied recombinant leukocyte A interferon

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-α2

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

The limited effect of nasal interferon induced by rhinovirus and a topical chemical inducer on the course of infection

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Prophylactic Effect of Low Doses of Human Leukocyte Interferon Against Infection with Rhinovirus

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Could preventive intranasal interferon lower the morbidity in children prone to respiratory illness?

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Viruses and bacteria in the etiology of the common cold

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Prevention and treatment of experimental influenza A virus infection in volunteers with a new antiviral ICI 130,685.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Evaluation of an interferon inducer in viral respiratory disease.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Tolerance and nasal histopathologic effects of long-term, low-dose intranasal recombinant interferon alpha-2A (Roferon-A).

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Prevention of illness from rhinovirus infection by a topical interferon inducer.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

The antiviral activity of isoquinoline drugs for rhinoviruses in vitro and in vivo

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Prevention of experimental coronavirus colds with intranasal alpha-2b interferon

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Recombinant human interferon-gamma as prophylaxis against rhinovirus colds in volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

A view from the Common Cold Unit

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Tolerance of one-month intranasal interferon

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Intranasal Interferon 2 for Prevention of Rhinovirus Infection and Illness

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Failure of human fibroblast interferon to protect against rhinovirus infection

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN-alpha Con1.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Inhibition of respiratory virus infection by locally applied interferon

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

The activity of enviroxime against rhinovirus infection in man

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Human Tolerance and Histopathologic Effects of Long-Term Administration of Intranasal Interferon- 2

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Clinical evaluation of prophylactic intranasal 1-phenyl-3-(4-phenyl-2-thiazolyl) guanidine (CL 88,277) medication against rhinovirus 44 challenge

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD002743.PUB2

Identifiers

DOI

10.1002/14651858.CD002743.PUB2

1 reference

25 July 2017

1 reference

PubMed ID

17636705